The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.
Tirzepatide increased time in target blood glucose.
It also decreased hypoglycemia compared to InsulinDegludec in the SURPASS-3 CGM sub-study.